Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Semaphorins, specifically type IV, are important regulators of axonal guidance and have been increasingly implicated in poor prognoses in a number of different solid cancers. In conjunction with their cognate PLXNB family receptors, type IV members have been increasingly shown to mediate oncogenic functions necessary for tumor development and malignant spread. In this study, we investigated the role of
semaphorin 4C
(
SEMA4C
) in
osteosarcoma
growth, progression, and metastasis. We investigated the expression and localization of
SEMA4C
in primary
osteosarcoma
patient tissues and its tumorigenic functions in these malignancies. We demonstrate that overexpression of
SEMA4C
promotes properties of cellular transformation, while RNAi knockdown of
SEMA4C
promotes adhesion and reduces cellular proliferation, colony formation, migration, wound healing, tumor growth, and lung metastasis. These phenotypic changes were accompanied by reductions in activated AKT signaling, G1 cell cycle delay, and decreases in expression of mesenchymal marker genes SNAI1, SNAI2, and TWIST1. Lastly, monoclonal antibody blockade of
SEMA4C
in vitro mirrored that of the genetic studies. Together, our results indicate a multi-dimensional oncogenic role for
SEMA4C
in metastatic osteosarcoma and more importantly that
SEMA4C
has actionable clinical potential.
...
PMID:SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis. 3158 36
